Marija Ger1, Algirdas Kaupinis2, Marius Petrulionis3,4, Benediktas Kurlinkus4, Jonas Cicenas2,5,6, Audrius Sileikis3,4, Mindaugas Valius2, Kestutis Strupas3,4. 1. Institute of Biochemistry, Proteomics Center, Vilnius University Life Sciences Center, Vilnius, Lithuania marija.ger@bchi.vu.lt. 2. Institute of Biochemistry, Proteomics Center, Vilnius University Life Sciences Center, Vilnius, Lithuania. 3. Center of Abdominal Surgery, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. 4. Clinic of Gastroenterology, Nephrourology and Surgery, Faculty of Medicine, Vilnius University, Vilnius, Lithuania. 5. MAP Kinase Resource, Bioinformatics, Bern, Switzerland. 6. Department of Microbiology, Immunology and Genetics, Max F. Perutz Laboratories, University of Vienna, Vienna, Austria.
Abstract
BACKGROUND/AIM: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer, particularly due to its aggressive course and challenging diagnostics in early-stage disease. The aim of this study was to discover new potential prognostic and diagnostic pancreatic cancer biomarkers. MATERIALS AND METHODS: The proteomes of 37 samples from pancreatic cancer, inflammatory or healthy pancreatic tissue derived through in-depth differential proteomic analysis were compared. RESULTS: A set of candidate proteins as pancreatic cancer-specific diagnostic or prognostic biomarkers were identified. Survival data of patients after two-year follow-up indicated FLT3 and PCBP3 proteins as potential biomarkers for favourable pancreatic cancer prognosis. The levels of PCBP3 correlated with tumour stage and FLT3 levels, were evaluated as independent prognostic marker. CONCLUSION: FLT3 and PCBP3 represent potential biomarkers for improved individualized pancreatic cancer prognosis. Moreover, FLT3 may play a role in future treatment selection. Copyright
BACKGROUND/AIM: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer, particularly due to its aggressive course and challenging diagnostics in early-stage disease. The aim of this study was to discover new potential prognostic and diagnostic pancreatic cancer biomarkers. MATERIALS AND METHODS: The proteomes of 37 samples from pancreatic cancer, inflammatory or healthy pancreatic tissue derived through in-depth differential proteomic analysis were compared. RESULTS: A set of candidate proteins as pancreatic cancer-specific diagnostic or prognostic biomarkers were identified. Survival data of patients after two-year follow-up indicated FLT3 and PCBP3 proteins as potential biomarkers for favourable pancreatic cancer prognosis. The levels of PCBP3 correlated with tumour stage and FLT3 levels, were evaluated as independent prognostic marker. CONCLUSION:FLT3 and PCBP3 represent potential biomarkers for improved individualized pancreatic cancer prognosis. Moreover, FLT3 may play a role in future treatment selection. Copyright
Authors: Mareike Waldenmaier; Lucas Schulte; Jonathan Schönfelder; Axel Fürstberger; Johann M Kraus; Nora Daiss; Tanja Seibold; Mareen Morawe; Thomas J Ettrich; Hans A Kestler; Christoph Kahlert; Thomas Seufferlein; Tim Eiseler Journal: Cancers (Basel) Date: 2022-02-21 Impact factor: 6.639